Submit tirzepatide for type 2 diabetes to regulatory authorities
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Aug 2021
- Due
- 31 Dec 2021
- Delivered
- by 31 Dec 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The company announced plans to submit donanemab for Alzheimer’s disease and tirzepatide for type 2 diabetes to regulatory authorities by the end of 2021.”
What we found
Evidence strength A What the grades mean
Eli Lilly confirmed in its 2022 filings that it submitted tirzepatide for type 2 diabetes to regulatory authorities in the U.S., Europe, and Japan during 2021.
-
A ELI Lilly & Co 10-Q filed 2022-04-29
“Tirzepatide Type 2 diabetesSubmittedSubmitted in the U.S. using a Priority Review Voucher and in Europe and Japan in 2021.” ✓ confirmed on the page
Market reaction: the shares moved -0.4% against the S&P 500 over the three sessions around the disclosure (28 Apr 2022 to 3 May 2022). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Submit
- Deliverable
- tirzepatide regulatory submission
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you ELI Lilly & Co? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-LLY-004212 · Corrections policy